• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

    0.2500 -0.0267 (-9.65%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mainz Biomed N.V. - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    It's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday! 
    Via InvestorPlace
    Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
    From Mainz BioMed NV
    Via GlobeNewswire
    10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar
    --News Direct-- 
    Via News Direct
    Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
    Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'... 
    Via Benzinga
    Exposures COVID-19
    Where Mainz Biomed Stands With Analysts
    Via Benzinga
    10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar
    The WHO reports that colorectal cancer is the second most fatal cancer around the world. 
    Via Benzinga
    Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
    From Mainz BioMed NV
    Via GlobeNewswire
    Second Most Fatal Cancer In U.S. May Face A Big Fight From Mainz Biomed’s Non-Invasive Test; (NASDAQ: MYNZ) Is Making Early Detection Possible
    --News Direct-- 
    Via News Direct
    Second Most Fatal Cancer In U.S. May Soon Face A Challenger: Mainz Biomed's (NASDAQ: MYNZ) Early Detection Tech
    Colorectal cancer is the third most common cancer worldwide, and although the majority of colorectal cancer cases have historically occurred in individuals aged 45 and older, it is increasingly... 
    Via Benzinga
    Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
    Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
    Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland 
    From Mainz BioMed NV
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
    From Mainz BioMed NV
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why US Steel Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
    Gainers AGBA Group Holding Limited (NASDAQ: AGBA) shares surged 49.4% to $1.31 in pre-market trading after the company reported a 325% year-over-year growth in its second-quarter revenue. 
    Via Benzinga
    Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
    Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
    Israel has one of the highest screening compliance rates in the world with over one million people being screened each year 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Secures up to $50M in New Funding
    Provides option to access capital to support commercial and clinical programs 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
    The Company’s innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Expands into Romania Through Partnership with Bioclinica
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Expands Commercial Footprint into Poland
    Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today 
    Via PressReach
    Topics Death
    Exposures Death
    Being Overweight or Obese Increases Risk of Developing Colorectal Cancer
    Maintaining a healthy weight is important for general health, but growing evidence reveals obesity’s role in the development of chronic illnesses and even deadly cancers. Obesity is one of the most... 
    Via PressReach
    Mainz Biomed Expands Commercial Footprint into Poland
    From Mainz BioMed NV
    Via GlobeNewswire
    BioNTech’s mRNA Vaccine Shows Early Potential Against Pancreatic Cancer
    One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system’s defense? One of the deadliest forms of cancer around,... 
    Via PressReach
    Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
    From Mainz BioMed NV
    Via GlobeNewswire
    A New Groundbreaking Tool to Detect Colon Cancer Earlier
    A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
    Via PressReach
    Exposures Product Safety
    Colon Cancer Creeping Into Younger Adults – New R&D Uncovers Early Signs
    Spots of blood after bowel movements, stomach aches, and protracted episodes of diarrhea may be symptoms of early-onset colorectal cancer, which is increasingly diagnosed in young adults who are... 
    Via PressReach
    Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
    From Mainz BioMed NV
    Via GlobeNewswire
    AI Tool Predicts Colon Cancer Survivorship and Response to Treatment
    Harvard Medical School and National Cheng Kung University in Taiwan have designed an artificial intelligence (AI) algorithm to improve colorectal cancer prognosis and treatment options. The new... 
    Via PressReach
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.